Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease.  Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates.  Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.

Biotechnology

Education

Avidity

Sarah Boyce

Scott Hager

Anneke Raney

Mike Flanagan

Mike MacLean

Joseph Johnston

Husam Younis

Elizabeth J Ackermann PhD

Michael MacLean

Steve Hughes

W. Michael Flanagan

John W. Wallen III

Teresa McCarthy

Arthur A. Levin

The Scientific Research Team at Avidity Biosciences is dedicated to advancing the development of antibody-siRNA conjugates (ASC™). Comprising scientists specialized in toxicology, bioinformatics, drug discovery, and biomarkers, the team collaborates to design, synthesize, and validate innovative ASC therapies targeting disease-associated mRNAs. Their work involves rigorous experimentation, clinical evaluation, and the optimization of drug-like properties to advance precision medicine solutions for genetic diseases.

Scientific Research Team

Clinical Operations Team

Leadership Team

Scientific Research Team

About

Team members